| Title |
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2013
|
| DOI | 10.2147/dddt.s51298 |
| Pubmed ID | |
| Authors |
Sarah Schleiferböck, Christian Scheurer, Masataka Ihara, Isamu Itoh, Ian Bathurst, Jeremy N Burrows, Pascal Fantauzzi, Julie Lotharius, Susan A Charman, Julia Morizzi, David M Shackleford, Karen L White, Reto Brun, Sergio Wittlin |
| Abstract |
The objective of this work was to characterize the in vitro (Plasmodium falciparum) and in vivo (Plasmodium berghei) activity profile of the recently discovered lead compound SSJ-183. The molecule showed in vitro a fast and strong inhibitory effect on growth of all P. falciparum blood stages, with a tendency to a more pronounced stage-specific action on ring forms at low concentrations. Furthermore, the compound appeared to be equally efficacious on drug-resistant and drug-sensitive parasite strains. In vivo, SSJ-183 showed a rapid onset of action, comparable to that seen for the antimalarial drug artesunate. SSJ-183 exhibited a half-life of about 10 hours and no significant differences in absorption or exposure between noninfected and infected mice. SSJ-183 appears to be a promising new lead compound with an attractive antimalarial profile. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| United States | 1 | 3% |
| Portugal | 1 | 3% |
| Uganda | 1 | 3% |
| Unknown | 26 | 87% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 17% |
| Researcher | 4 | 13% |
| Other | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 6 | 20% |
| Unknown | 8 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 6 | 20% |
| Chemistry | 6 | 20% |
| Medicine and Dentistry | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Computer Science | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 9 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2014.
All research outputs
#4,604,901
of 25,460,914 outputs
Outputs from Drug Design, Development and Therapy
#277
of 2,272 outputs
Outputs of similar age
#40,265
of 226,851 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 40 outputs
Altmetric has tracked 25,460,914 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,272 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,851 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.